TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Open Orphan Plc ( (GB:HVO) ) just unveiled an update.
hVIVO plc announced that its client, Cidara Therapeutics, has been acquired by Merck Sharp & Dohme LLC for approximately $9.2 billion following positive results from a Phase IIb trial of Cidara’s lead candidate, CD388. This acquisition highlights hVIVO’s role in accelerating drug development and underscores its strategic importance in supporting breakthrough therapies. hVIVO has been instrumental in the development of CD388, providing critical data from early proof-of-concept to late-stage trials, and continues to support its Phase III development. The company’s ability to execute large-scale field studies and its diversification into standalone laboratory services are validated by this transaction.
The most recent analyst rating on (GB:HVO) stock is a Hold with a £6.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on GB:HVO Stock
According to Spark, TipRanks’ AI Analyst, GB:HVO is a Neutral.
The overall stock score of 65 reflects strong financial performance and attractive valuation, offset by bearish technical indicators. The company’s robust revenue growth and profitability are significant strengths, while the current market momentum suggests caution. The low P/E ratio and dividend yield highlight potential undervaluation, making it appealing for value investors.
To see Spark’s full report on GB:HVO stock, click here.
More about Open Orphan Plc
hVIVO plc is a full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The company provides end-to-end clinical development services to a diverse client base, including major biopharma companies. Specializing in infectious and respiratory indications, hVIVO operates the largest quarantine facility in London and offers virology and immunology laboratory services under the hLAB brand. Through its subsidiaries, CRS and Venn Life Sciences, hVIVO offers clinical trial services and drug development consulting across Europe.
Average Trading Volume: 2,133,668
Technical Sentiment Signal: Sell
Current Market Cap: £39.5M
See more data about HVO stock on TipRanks’ Stock Analysis page.